ClinicalTrials.gg
RecruitingNCT07672574Updated Sep 11, 2026

Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers

A Phase 1 interventional study of Ontunisertib and [14C]ontunisertib in Fibrostenotic Crohn's Disease, sponsored by Agomab Spain S.L.U.. Recruiting at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Agomab Spain S.L.U. (part of Agomab Therapeutics NV) · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
30 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 217 studies in Crohn Disease with a site in United Kingdom — 47 open to participants now, 66 under way, 26 of them phase 3. Crohn Disease · United Kingdom.

Planned enrollment
166th of 171
8 · median 168
Started
2026
with 8 others
Phase 1
10 of 217
2 open now
Primary completion
2026-09
later than 16 of 65 live
Registered
214th of 217
by date

Among the 217 studies in Crohn Disease with a site in United Kingdom, this one is the 166th largest by planned enrollment of the 171 interventional ones that give a count, is one of 9 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 16 of the 65 other live ones, and was the 214th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

47 of the 217 studies in Crohn Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 30 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Crohn Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

This is an open, two-part study in healthy male volunteers, aged 30-65 years.

This trial aims to understand how the human body absorbs, distributes, metabolizes and eliminates ontunisertib after a single oral dose of radiolabelled test medicine ([14C]ontunisertib) and determine the routes and rates of elimination of the test medicine.

Read the detailed description

This is an open, two-part study in healthy male volunteers, aged 30-65 years with the trial duration of approximately 7 weeks.

In Part 1 of this study, healthy volunteers will be given a dose of test medicine orally followed by an intravenous injection of a very small dose of radiolabelled test medicine that contains a tiny amount of radioactivity (called carbon-14) so that the test medicine can be traced in the blood.

In Part 2, single doses of test medicine will be administered orally to find out how the body breaks down and gets rid of the test medicine. The test medicine will be 'radiolabelled' - it will contain a small amount of radioactivity (Carbon-14) - so that it can be traced in the body.

Participants will take part in both study parts and will remain resident in the clinic for up to 10 days after their final dose of Investigation Medicinal Product (IMP). After the participants have left the clinic, they may have to collect their urine and faeces at home until mass balance criteria has been met.

Over a period of at least 8 days in Part 1 and 10 days in Part 2, many blood samples will be taken, and volunteers will collect all their urine and faeces so that the amount of test medicine and its breakdown products can be measured/analysed.

A blood sample will be taken from volunteers between admission and first dose for pharmacogenetic testing.

03

Conditions studied

  • Fibrostenotic Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males aged 30 to 65 years inclusive at the time of signing
  • Must agree to the use of an adequate method of for up to 93 days post-final dose
  • Healthy male participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12-lead , and laboratory safety tests without any abnormalities.
  • of 18.0 to 29.9 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Serious adverse reaction or serious to any drug or formulation
  • History of renal, hepatic, respiratory, particularly GI disease, especially peptic ulceration, clinically significant GI bleeding, ulcerative colitis, Crohn's Disease or Irritable Bowel Syndrome, and neurological or psychiatric disorder
  • History of GI surgery (with the exception of appendectomy or hernia repair unless it was performed within the previous 12 months)
  • Clinically significant abnormal clinical chemistry, hematology, coagulation or urinalysis as judged by the investigator at screening.
  • Radiation exposure, including that from the present trial, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker shall participate in the trial
  • Participants who have been administered IMP in an ADME trial or any trial involving administration of 14C radioactivity in the last 12 months
  • Male participants with pregnant or lactating partners
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Ontunisertib

    Participants will receive single oral dose of ontunisertib

    Drug: Ontunisertib

  • Experimental
    [14C]ontunisertib solution for infusion

    Participants will receive single IV dose of \[14C\]ontunisertib

    Drug: [14C]ontunisertib

  • Experimental
    [14C]ontunisertib

    Participants will receive single oral dose of \[14C\]ontunisertib

    Drug: [14C]ontunisertib

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability of ontunisertib following oral and IV administration

    Part 1: To determine the absolute oral bioavailability of ontunisertib

    Time frame: Through study completion, an average of 8 days

  2. Cumulative amount of total radioactivity excreted in urine and feces

    Part 2: To determine the mass balance recovery after a single oral dose of \[14C\]ontunisertib

    Time frame: Through study completion, an average of 10 days

  3. Chemical structure of each metabolite accounting for ≥10% of circulating total radioactivity and Metabolite profiling accounting for >80% of total radioactivity recovered in urine and/or feces

    Part 2: To characterize the metabolite profile in plasma and excreta (urine and/or feces) after a single oral dose of \[14C\]ontunisertib

    Time frame: Through study completion, an average of 10 days

Secondary outcomes

  1. PK parameter (AUClast)

    Part 1: To characterize the IV PK (AUClast) of \[14C\]ontunisertib and total radioactivity in plasma

    Time frame: Through study completion, an average of 8 days

  2. Cumulative amount of total radioactivity excreted in urine and feces following IV administration

    Part 1: To determine the mass balance recovery after a single IV dose of \[14C\]ontunisertib

    Time frame: Through study completion, an average of 8 days

  3. PK parameter (AUClast)

    Part 1 and Part 2: To characterize the plasma PK (AUClast) of ontunisertib and metabolites and total radioactivity (Part 2 only) following a single oral dose

    Time frame: Through study completion, an average of 18 days

  4. Whole blood-to-plasma concentration ratios for total radioactivity

    Part 2: To evaluate the extent of distribution of total radioactivity into blood cells

    Time frame: Through study completion, an average of 10 days

  5. Number of participants with adverse events (AEs)

    Part 1 and Part 2: To assess the safety and tolerability of ontunisertib

    Time frame: Through study completion, an average of 18 days

  6. Number of participants with abnormal physical examinations

    Part 1 and Part 2: To assess the safety and tolerability of ontunisertib

    Time frame: Through study completion, an average of 18 days

  7. Number of participants with abnormal vital signs

    Part 1 and Part 2: To assess the safety and tolerability of ontunisertib

    Time frame: Through study completion, an average of 18 days

  8. Number of participants with abnormal ECGs parameters

    Part 1 and Part 2: To assess the safety and tolerability of ontunisertib

    Time frame: Through study completion, an average of 18 days

  9. Number of participants with abnormal clinical laboratory safety tests

    Part 1 and Part 2: To assess the safety and tolerability of ontunisertib

    Time frame: Through study completion, an average of 18 days

  10. Chemical structure analysis of metabolites accounting for ≥10%

    Part 1: To characterize the metabolites profile in plasma following an IV dose of \[14C\]ontunisertib

    Time frame: Through study completion, an average of 8 days

07

Study locations

1 of 1 sites recruiting
  • Quotient Sciences Limited
    Nottingham, NG11 6JS, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2026, 0 months after the start.

Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 0 months is below that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 29, 2026
StartActual
Sep 9, 2026
Primary completionEst.
Sep 26, 2026
CompletionEst.
Sep 26, 2026
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07672574
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Sep 9, 2026
Primary completion
Sep 26, 2026 (estimated)
Completion
Sep 26, 2026 (estimated)
Last update
Sep 11, 2026

Study contacts

Agomab Clinical Operations
Contact
clinicalstudies@agomab.com
0032 3318 91 70
Silke Hüttner, MD
study director · Agomab Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontunisertib

Start the discussion